-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 17, ESMO Virtual Plenary Resources released the results of the PEARLS/KEYNOTE-091 (NCT02504372) study
.
The study evaluated the efficacy of pembrolizumab as adjuvant therapy in patients with completely resected early-stage non-small cell lung cancer ( NSCLC )
Lung cancerNSCLC
The KEYNOTE-091 study also used the AJCC 7th edition of the lung cancer staging system, but postoperative platinum-containing adjuvant therapy was not necessary.
The study included R0, IB stage (T ≥ 4 cm, stage II or IIIA NSCLC), 1:1 Randomized to pembrolizumab or placebo
.
Baseline characteristics were balanced between groups
.
In the overall population, pembrolizumab significantly improved DFS (53.
In the subgroup analysis, it can be seen that the HRs of those who received adjuvant chemotherapy and those who did not receive chemotherapy were 0.
The safety profile of pembrolizumab in the study was as expected
CONCLUSIONS: Adjuvant pembrolizumab for completely resected stage IB (T ≥ 4 cm)-IIIA NSCLC patients regardless of PD-L1 expression (regardless of PD-L1 TPS <1%, 1-49%, ≥50% ) provided a statistically significant, clinically meaningful improvement in DFS
Statistics leave a message here